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Hepatitis C virus (HCV) protease inhibitor resistance-associated substitutions are
selected during triple-therapy breakthrough. This multicenter quality control study
evaluated the expertise of 23 French laboratories in HCV protease inhibitor
resistance genotyping. A panel of 12 well-defined blinded samples comprising two
wild-type HCV strains, nine transcripts from synthetic NS3 mutant samples or from
clinical strains, and one HCV RNA-negative sample was provided to the
participating laboratories. The results showed that any laboratory with expertise in
sequencing techniques should be able to provide reliable HCV protease inhibitor
resistance genotyping. Only a 0.7% error rate was reported for the amino acid sites
studied. The accuracy of substitution identification ranged from 75% to 100%,
depending on the laboratory. Incorrect results were mainly related to the
methodology used. The results could be improved by changing the primers and
modifying the process in order to avoid cross-contamination. This study underlines
the value of quality control programs for viral resistance genotyping, which is
required prior to launching observational collaborative multicenter studies on HCV
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